

Science of 2019 Biotech IPOs

drughunter.com

Small Molecule R&D Companies Listed on NYSE/NASDAQ in 2019 by IPO Mkt. Cap.

Company	SYMB	Cap. (M)	Lead Mechanisms	Stage	Other Programs
BridgeBio Pharma	BBIO	\$2,000	for genetic diseases incl. cancer (e.g.): oral TTR stabilizer for ATTR-CM, FGFR1-3 inhibitor for cancer	Ph. 3	>10 targets (RAS, HH, CaSR, PI3K α , G α , PanK, PI3K β , KLK5/7, GPX4, KRAS, SHP2)
Gossamer Bio	GOSS	\$1,100	oral DP2 antagonist for inflammation	Ph. 2	PDGFR, HIF-1 α , CD11b
SpringWorks Therapeutics	SWTX	\$798	oral γ -secretase inhibitor for cancer	Ph. 3	MEK1/2i, RAF
Phathom Pharmaceuticals	PHAT	\$681	K ⁺ -competitive acid blocker for GI	Ph. 3	--
Turning Point Therapeutics	TPTX	\$578	oral ROS1/TRK/ALK inhibitor active against clinical solvent-front mutants	Ph. 1/2	RET/SRC, MET/CSF1R/SRC, ALK
Frequency Therapeutics	FREQ	\$480	hair cell progenitor activators for hearing restoration	Ph. 2	multiple sclerosis
Cortexyme	CRTX	\$476	gingipains inhibitor targeting <i>P. gingivalis</i> in Alzheimer's patients	Ph. 2/3	protease inhibitors
Morphic Therapeutic	MORF	\$465	MORF-057, α 4 β 7 integrin inhibitor	Pre-C.	α _v β ₆
Karuna Therapeutics	KRTX	\$456	M1,M4 agonist + non-BP MR antagonist combo for psychosis	Ph. 2	muscarinic
Fulcrum Therapeutics	FULC	\$386	p38 α , β kinase inhibitor for DUX4 expression inhibitor in FSHD	Ph. 2	HBG1/2, UTRN, FXN, DMPK SNCA
Milestone Pharmaceuticals	MIST	\$385	nasal Ca ²⁺ -channel blocker for rapid termination of PSVT events	Ph. 3	--
Mirum Pharmaceuticals	MIRM	\$377	gut-restricted ASBT inhibitors for cholestatic liver diseases	NDA filing	--
Oyster Point	OYST	\$362	nasal nAChR agonist for dry eye disease	Ph. 3	--
Aprea Therapeutics	APRE	\$335	reactivator of mutant p53	Ph. 3	oral p53 mutant act.
Galera Therapeutics	GRTX	\$317	dismutase mimetics for radiotherapy (SOM)	Ph. 3	GC4419 for esophagitis
Satsuma Pharmaceuticals	STSA	\$270	nasal dihydroergotamine for acute treatment of migraine	Ph. 3	--
RAPT Therapeutics	RAPT	\$261	CCR4 inhibitor for immunotherapy	Ph. 2	asthma CCR4i, GCN2, HPK1
IDEAYA Biosciences	IDYA	\$204	IDE196 (PKC inhibitor)	Ph. 1	MAT2A, Pol- θ , WRN, PARG
Applied Therapeutics	APLT	\$188	systemic or restricted aldose reductase inhibitors for cardiomyop., galactosemia	Ph. 3	PI3K δ , γ
Trevi Therapeutics	TRVI	\$184	μ OR antag./kOR agonist for neurology	Ph. 3	--
TFF Pharmaceuticals	TFFP	\$89	thin film freezing formulations for inhal.	Ph. 1	tacrolimus, COPD/asthma
Anchiano Therapeutics	ANCN	\$85	pan-RAS inhibitors	Pre-C.	PDE10/ β -catenin
Monopar Therapeutics	MNPR	\$83	clonidine form. for radiotherapy (SOM)	Ph. 3,	doxorubicin analog
CNS Pharmaceuticals	CNSP	\$63	brain-penetrant anthracycline	Ph. 1	other CNS cancers
Hoth Therapeutics	HOTH	\$56	DTPA zinc chelator + antibiotic	Pre-C.	--

*as of Feb. 9, 2020

drug
hunter